author-photo

Mara Bonelli

University of Parma

67

Papers

1835

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (2)
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells.

2021 Cells
Show All
- Source
- Cite
- Save
Citations (1)
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

2020 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (6)
Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immunomodulation.

2019 Biochemical Pharmacology
Show All
- Source
- Cite
- Save
Citations (28)
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

2019 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (33)
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

2019 Journal of Experimental & Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (20)
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells

2018
Show All
- Source
- Cite
- Save
Citations (4)
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (19)